FreshBurst Listerine Study Must Exhibit 20% Gingivitis Reduction – FDA
This article was originally published in The Rose Sheet
Executive Summary
A six-month study of FreshBurst Listerine with Fluoride will need to show "a 20% reduction in gingivitis" over a control to merit agency sign-off, FDA told Pfizer execs at an OTC "feedback" meeting Aug. 27
You may also be interested in...
Combination Oral Health Care Products Lack Sufficient Safety Data – J&J
Johnson & Johnson argues against including combination oral health care products in the OTC antingingivitis/antiplaque monograph in Nov. 25 comments to FDA
Combination Oral Health Care Products Lack Sufficient Safety Data – J&J
Johnson & Johnson argues against including combination oral health care products in the OTC antingingivitis/antiplaque monograph in Nov. 25 comments to FDA
Combination Oral Health Care Product Safety Defended By Industry
Combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association